Bavencio Európai Unió - magyar - EMA (European Medicines Agency)

bavencio

merck europe b.v. - avelumab - neuroendokrin tumorok - egyéb daganatellenes szerek, monoklonális antitestek - a bavencio-t monoterápiaként említik metasztatikus merkel-sejtes karcinóma (mcc) felnőtt betegek kezelésére,. bavencio kombinálva axitinib javallott az első-vonalbeli kezelésére felnőtt betegek előrehaladott vesesejtes carcinoma (rcc). bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc) who are progression-free following platinum‑based chemotherapy.

Idefirix Európai Unió - magyar - EMA (European Medicines Agency)

idefirix

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunszuppresszánsok - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Adakveo Európai Unió - magyar - EMA (European Medicines Agency)

adakveo

novartis europharm limited - crizanlizumab - anémia, sarlósejt - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Spevigo Európai Unió - magyar - EMA (European Medicines Agency)

spevigo

boehringer ingelheim international gmbh - spesolimab - pikkelysömör - immunszuppresszánsok - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Zynlonta Európai Unió - magyar - EMA (European Medicines Agency)

zynlonta

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - daganatellenes szerek - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.